

3 August 2023

ASX ANNOUNCEMENT

Notice received under section 249D of the Corporations Act

ImpediMed Limited (**ImpediMed** or the **Company**) (ASX: IPD) advises that in accordance with ASX Listing Rule 3.17A it has received a notice under section 249D of the *Corporations Act 2001* (Cth) (**Corporations Act**) from the shareholders listed in the Schedule (**Requisitioning Parties**) holding at least 5% of the votes that may be cast at a general meeting of the Company.

The Requisitioning Parties have requested that the directors of the Company call and arrange to hold a general meeting of the Company for the purposes of considering eight proposed resolutions, of which:

- four resolutions are proposed for the removal of each of Don Williams, Amit Patel, David Anderson and Daniel Sharp as directors of the Company; and
- four resolutions are proposed for the appointment of each of McGregor Grant, Christine Emmanuel-Donnelly, Andrew Grant and Janelle Delaney as directors of the Company.

The Company has also received a members' statement under section 249P of the Corporations Act which will be circulated to shareholders in accordance with the Company's requirements under the Corporations Act. The members' statement outlines the rationale of the requisition, being a perceived disconnect between the Australian shareholders and the present board relating to the Company's recent capital raising and perceived risks to shareholder wealth. The company will respond to the statement in due course.

The Company is considering the notices and will keep shareholders updated on any material developments, including the timing of the general meeting. The general meeting will be held no later than 2 October 2023, being two months after the section 249D request was given to the Company.

If shareholders have any questions on this matter, they are welcome to direct their queries to the Managing Director and Chief Executive Officer, Rick Valencia.

Authorised for release by the Chair of the Board of Directors and the Chief Executive Officer of ImpediMed Limited.

Contact Details

Investor Relations Contact:

Hannah Howlett

WE Communications

T: +61 450 648 064

E: hhowlett@we-worldwide.com

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Schedule of Requisitioning Parties

Matra Capital Pty Ltd (ACN 619 614 541) in its capacity as trustee of Namur Unit Trust

Jonnola Pty Ltd (ACN 104 557 842) in its capacity as trustee of Scales Super Fund

Jonnola Pty Ltd (ACN 104 557 842) in its capacity as trustee of The Scales Unit Trust

Pakasoluto Pty Limited (ACN 078 860 572) as trustee of Barkl Family Super Fund A/C

Henderson International Pty. Limited (ACN 060 565 291) as trustee of Henderson Super Fund

Henderson International Pty. Limited (ACN 060 565 291) as trustee of Skibo Super Fund

Henderson International Pty. Limited (ACN 060 565 291) as trustee of Sowers & Reapers Family Account

Stephen Mahnken and Dior Mahnken as joint trustees of Three Fish Trust

MBA Investments Pty Ltd (ACN 152 926 531)

Sunlora Pty. Limited (ACN 067 298 006) as trustee of Three Fish Superannuation

Moore Family Nominee Pty Limited (ACN 081 330 832) as trustee of Moore Family Super Fund

Standard Company Pty Ltd (ACN 149 923 311) as trustee of 26 Broadway Trust

Acadia Park Pty Ltd (ACN 629 581 326)

S A Funds Pty Limited (ACN 111 818 752) as trustee of SA Super Fund

LAYF Pty Ltd (ACN 124 962 956) as trustee of Luan & Yoong Foundation

Wales Corporation Pty. Ltd. (ACN 078 446 867)